Harmony Biosciences Holdings (HRMY) Finished Goods (2023 - 2024)
Harmony Biosciences Holdings recorded quarterly Finished Goods of $2.8 million in Q4 2024, down 17.04% quarter-over-quarter from $3.3 million in Q3 2024, and up 21.11% year-over-year from $2.3 million in Q1 2024.
Harmony Biosciences Holdings' Finished Goods history runs 2 years deep, the most recent figure standing at $2.8 million for Q4 2024.
- In Q4 2024, Finished Goods rose 21.11% year-over-year to $2.8 million; the TTM figure through Dec 2024 stood at $2.8 million (up 21.11% YoY), while the FY2024 annual figure was $2.8 million, up 21.11% from the prior year.
- Finished Goods came in at $2.8 million for Q4 2024 at Harmony Biosciences Holdings, down from $3.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $3.3 million in Q3 2024 to a low of $2.3 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Harmony Biosciences Holdings | 1.83 Bn | 1.19 Bn | 170.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.77 Mn |
| Sep 30, 2024 | 3.33 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 2.28 Mn |